Financial Comparison
Johnson & Johnson vs Pfizer Inc
Click a ticker to view the full analysis.
In short
Johnson & Johnson is the more profitable of the two, keeping 28.5% of revenue as net profit against 12.4% for Pfizer Inc. Pfizer Inc trades at the higher trailing P/E (44.7× vs 39.1× for Johnson & Johnson), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Johnson & Johnson and 1 for Pfizer Inc.
Based on filings for periods ending 27 Sept 2026 (JNJ) and 27 Sept 2026 (PFE) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. JNJ shown solid · PFE shown dashed. Not financial advice.
| Metric | JNJ | PFE |
|---|---|---|
| Price | $257.78 | $31.27 |
| Market Cap | $621.2B | $178.2B |
| P/E (TTM) | 39.1x | 44.7x |
| P/B | 7.3x | 2.1x |
| Beta | 0.21 | 0.30 |
| Div Yield | 2.07% | 5.59% |
| Revenue (TTM) | $94.2B | $62.6B |
| Net Income | $26.8B | $7.8B |
| Gross Margin | 67.9% | — |
| Risk Flags | 1 flag | 2 flags |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.